海普瑞：IVENOXIN获得南非批准

格隆汇2025-04-24

格隆汇4月24日丨海普瑞(09989.HK)公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液（商品名：Ivenoxin）已获得南非健康产品监管局(SAHPRA)上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。未来，集团将持续发力加速...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529609676?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 18:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2529609676","market":"hk","top_or_hot":-1,"title":"海普瑞：IVENOXIN获得南非批准","media":"格隆汇","content":"<div>\n<p>格隆汇4月24日丨海普瑞(09989.HK)公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液（商品名：Ivenoxin）已获得南非健康产品监管局(SAHPRA)上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。未来，集团将持续发力加速...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424182855a4653536&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海普瑞：IVENOXIN获得南非批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海普瑞：IVENOXIN获得南非批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 18:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424182855a4653536&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇4月24日丨海普瑞(09989.HK)公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液（商品名：Ivenoxin）已获得南非健康产品监管局(SAHPRA)上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。未来，集团将持续发力加速...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424182855a4653536&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424182855a4653536&s=b","article_id":"2529609676","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424182855a4653536&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2529609676","pubTimestamp":1745490535,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇4月24日丨海普瑞公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液已获得南非健康产品监管局上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","09989":"海普瑞"},"translate_title":"Hepalink: IVENOXIN Receives South African Approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1},"content_text":"格隆汇4月24日丨海普瑞(09989.HK)公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液（商品名：Ivenoxin）已获得南非健康产品监管局(SAHPRA)上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。未来，集团将持续发力加速全球市场拓展与销售管道建设，为深化海外市场发展奠定基础。截至本公告日，集团依诺肝素钠制剂已获准在中国、美国、欧盟、英国、瑞士、波兰、巴西、哥伦比亚、智利、加拿大、沙乌地阿拉伯、阿联酋、马来西亚、澳大利亚、纽西兰、泰国、阿根廷等全球50多个国家和地区销售。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529609676","isCrawlerRequest":true}